Privately-owned global animal health and nutrition company, Huvepharma^®,  has acquired the global rights for the full OptiPhos^® phytase brand, product and registrations from Enzyvia^® LLC.

OptiPhos is an E. coli 6-phytase, first marketed in 2006 in the United States and now sold in 47 countries around the world. The addition of the global rights of OptiPhos^® is an extension to Huvepharma's existing enzyme business. Huvepharma^® has previously marketed and distributed OptiPhos^® as a partner of Enzyvia LLC for different countries in the Middle East, Europe, Africa and Asia.

Along with the OptiPhos^® brand, all related patents, intellectual property, trademarks, global regulatory registrations, and production assets are included in this transaction. This acquisition gives Huvepharma^® a global position with the Optiphos^® current product range, concentrations, and services. This will be continued by Huvepharma^® during the transition and beyond.

Enzyvia LLC, a wholly owned subsidiary of JBS United, is a global company based in Sheridan, Indiana that researches, develops and commercialises value-added feed additives for animal production and improvement.